Premium
Interstitial Cystitis and the Therapeutic Effect of Suplatast Tosilate
Author(s) -
HAYASHI Yukio,
UEDA Tomohiro,
KIRIMOTO Tsukasa,
NAKANO Koushi,
OKA Toshinori,
KINIWA Mamoru,
YOSHIMURA Naoki
Publication year - 2009
Publication title -
luts: lower urinary tract symptoms
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.451
H-Index - 15
eISSN - 1757-5672
pISSN - 1757-5664
DOI - 10.1111/j.1757-5672.2009.00044.x
Subject(s) - interstitial cystitis , medicine , urinary urgency , urinary system , immunoglobulin e , urinary bladder , abdominal pain , concomitant , urinary retention , mast cell , gastroenterology , urology , immunology , overactive bladder , antibody , pathology , alternative medicine
Painful bladder syndrome (PBS)/interstitial cystitis (IC) can be a chronic and debilitating disease characterized by urinary urgency, frequency, and bladder pain, which are often very difficult to treat, regardless of currently‐proposed treatments. Suplatast tosilate (IPD‐1151T) is an immunoregulator that suppresses Th2 cytokine production, immunoglobulin E (IgE) synthesis, chemical mediator release from mast cells, and eosinophilic recruitment. In a preliminary, open‐label clinical study of IPD‐1151T in 14 women with IC, treatment with IPD‐1151T significantly increased bladder capacity and decreased urinary urgency, urinary frequency, and lower abdominal pain, as measured by the IC symptom index, in patients with non‐ulcerative IC. A concomitant reduction in immunological parameters (eosinophils, IgE, and urine T cells) was observed. Also, in basic experimental studies using hydrochloric acid‐induced chronic cystitis rats, the oral administration of IPD‐1151T (0.1–100 mg/kg/day) for 7 days after the induction of cystitis dose dependently increased the intercontraction intervals and micturition volume. In addition, the infiltration of mast cells and eosinophils into the bladder was suppressed by IPD‐1151T. These findings suggest that IPD‐1151T could be a new medicine for treating debilitating symptoms, such as bladder pain and urinary frequency in PBS/IC.